Use of anti-apoptotic BCL-2 family protein inhibitors such as venetoclax, navitoclax, Obatoclax, TW-37, BM-1197, S63845, and AZD-5991 for induction of apoptosis in cancer cells has been reported (Neuzil et al. 2013; Ashkenazi et al. 2017; Kotschy et al. 2016; Tron et al. 2018; Cournoyer et al. 2019; Ahn et al. 2019; Sun et al. 2019). Here, BCL2 is linked to cancer.